# AskGene Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/askgene-pharma

- Industry: Biotechnology
- Headquarters: Camarillo, US
- Website: www.ask-gene.com
- Total disclosed funding: $20M
- Latest round: Series A (May 8, 2022)
- Investors on record: 2

## About

Based in California, US, and founded in 2012, AskGene Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops a biological drug for oncology and autoimmune disease treatment. In May 2022, AskGene Pharma, Inc. raised USD 20 million in a Series A funding co-led by Qiming Venture Partners and TF Capital. As of May 2022, Jeff Lu is the CEO of AskGene Pharma, Inc.

The product line of AskGene Pharma includes cytokine prodrugs and antibodies that target the immune cells of a wide range of digestive tract cancers, such as gastric, pancreatic, esophageal, and liver cancers. The company is also developing cytokine fusion molecules for the treatment of inflammatory disorders and autoimmune diseases. In addition, the firm is also developing ASKG712 to address specific needs in ophthalmology, including diabetic macular edema (DME), and wet age-related macular degeneration (wAMD). AskGene uses SmartKine platform to develop these novel biological drugs.

The company plans to use its proceeds from May 2022 funding for the development of its SmartKine cytokine prodrug platform and advance the clinical development of its therapeutic candidates.

## Funding rounds

- Series A, May 8, 2022, $20M — Qiming Venture Partners, TF Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A
- TF Capital — Series A